2026-06-08T14:21:54-05:00 2025-12-31 390974031 WEGNER CPAS LLP 419 N LEE ST ALEXANDRIA VA 223142301 990 2025-01-01 821199380 GLOBAL COALITION FOR ADAPTIVE RESEARCH INC GLOB 4154948020 700 LARKSPUR LANDING CIRCLE 199 LARKSPUR CA 949391754 MEREDITH BUXTON CFO/COO 4154948020 2026-06-05 1 GLENN MILLER CPA P00086726 7035190990 2026-06-05 2025 2025-03-06 01:10:19Z MEREDITH BUXTON 700 LARKSPUR LANDING CIRCLE 199 LARKSPUR CA 949391754 32444163 0 X GCARESEARCH.ORG X 2017 MD PIONEERING COLLABORATIVE, INNOVATIVE CLINICAL TRIALS TO SPEED THE DISCOVERY AND DEVELOPMENT OF CURES. 8 5 40 5 0 0 1668304 1028577 24168345 29534891 1851839 1880695 0 0 27688488 32444163 16019 19670 0 0 7624837 7841936 0 0 0 23254301 24746203 30895157 32607809 -3206669 -163646 63602270 78149775 24355112 33920568 39247158 44229207 X OUR MISSION IS PIONEERING COLLABORATIVE, INNOVATIVE CLINICAL TRIALS TO SPEED THE DISCOVERY AND DEVELOPMENT OF CURES. 0 0 27443955 19670 26667789 GBM AGILE (GLIOBLASTOMA ADAPTIVE GLOBAL INNOVATIVE LEARNING ENVIRONMENT) IS UNIQUELY DESIGNED AS A LONG-STANDING PLATFORM WITH THE ABILITY TO TEST MULTIPLE THERAPIES AT THE SAME TIME AGAINST A COMMON CONTROL (OR STANDARD OF CARE). THE PURPOSE IS TO EVALUATE MULTIPLE INVESTIGATIONAL TREATMENTS FOR EITHER NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA TO DETERMINE IF ANY OF THESE STUDY TREATMENT(S) IMPROVE OVERALL SURVIVAL AS COMPARED TO STANDARD TREATMENTS. 2463891 0 2867102 OTHER ONGOING PROGRAMS OR PROGRAMS IN DEVELOPMENT GCAR SERVES AS THE REGULATORY SPONSORSHIP OF THE MILITARY AND VETERANS PTSD ADAPTIVE PLATFORM CLINICAL TRIAL (M-PACT). PARTNERING WITH OPERATIONAL MEDICAL SYSTEMS, PART OF THE DEFENSE HEALTH AGENCY, GCAR IS CONDUCTING AN ADAPTIVE PLATFORM TRIAL AT IS EVALUATING MULTIPLE PHARMACOTHERAPEUTIC INTERVENTIONS FOR THE TREATMENT OF PTSD FOR ACTIVE-DUTY SERVICE MEMBERS AND VETERANS WITH PTSD AT MULTIPLE CLINICAL SITES IN THE US. THIS PROGRAM IS SUPPORTED BY A PROJECT TEAM THAT ALSO INCLUDES REPRESENTATIVES FROM THE U.S. AIR FORCE, ARMY, NAVY, AND SPECIAL OPERATIONS COMMAND. GCAR IS COMMITTED TO DESIGNING, LAUNCHING, AND OVERSEEING SEVERAL INITIATIVES CURRENTLY IN DEVELOPMENT TO RAPIDLY AND EFFICIENTLY EVALUATE NEW TREATMENTS FOR RARE AND LETHAL DISEASES, INCLUDING PANCREATIC CANCER, BILIARY TRACT CANCER, HIGH AND LOW GRADE SEROUS OVARIAN CANCER, AND NEUROFIBROMATOSIS. GCAR ALSO SUPPORTS EDUCATION, OUTREACH, AND CLINICAL COMMUNITY ENGAGEMENT TO ADDRESS THESE URGENT UNMET NEEDS. 29907846 1 1 0 0 0 0 0 0 0 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 16 0 40 1 0 0 0 0 0 0 0 0 0 0 1 0 X 8 5 0 0 1 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X RACHAEL COLEMAN 4154948020 700 LARKSPUR LANDING CIRCLE STE 199 LARKSPUR CA 949391754 GARY GORDON MD PHD SENIOR MEDICAL ADVISOR AND DIRECTOR 2.00 1.00 X 76342 0 0 TIMOTHY CLOUGHESY MD CHIEF MEDICAL OFFICER AND DIRECTOR 6.00 1.00 X X 215625 0 0 WK ALFRED YUNG MD DIRECTOR 2.00 1.00 X 16928 0 0 FARAMARZ YOUSEFZADEH JD LLM CHAIRMAN OF THE BOARD 5.00 1.00 X 0 0 0 BRIAN ALEXANDER MD MPH DIRECTOR 2.00 1.00 X 0 0 0 SUJUAN BA PHD DIRECTOR 2.00 1.00 X 0 0 0 JOHN FRISHKOPF MMS DIRECTOR 2.00 1.00 X 0 0 0 WEBSTER CAVENEE PHD DIRECTOR 2.00 1.00 X 0 0 0 MATTHEW VIVA DIRECTOR, LEGAL/SECRETARY 40.00 1.00 X 245350 0 31244 MEREDITH BUXTON CHIEF EXECUTIVE OFFICER/PRESIDENT 40.00 1.00 X 1269450 0 52165 RACHAEL COLEMAN CFO/COO/TREASURER 40.00 1.00 X 541250 0 31098 ASHLEY POWELL VICE PRESIDENT, TRIAL OPERATIONS 40.00 X 520625 0 13882 ROBERT MURRAY CHIEF BUSINESS AND STRATEGY OFFICER 40.00 X 812461 0 15200 RACHEL ROSENSTEIN SISSON COMMUNITY ENGAGEMENT/TRAINING LEAD 40.00 X 266440 0 19558 SARAH UNTCH DIRECTOR, TRIAL OPERATIONS 40.00 X 246909 0 29119 TRACEY ROBERTS DIRECTOR, QUALITY AND NEW INITIATIVES 40.00 X 255150 0 30075 HEATHER KLING DIRECTOR, CLINICAL SCIENCE 40.00 X 216304 0 20013 NAWEEN TAMJIDI SR. MGR,TRIAL OPERATIONS 40.00 X 197883 0 16395 4880717 0 258749 26 0 1 0 IQVIA 1700 PERIMETER PARK DR MORRISVILLE NC 27560 CRO SERVICES 14683453 MEDIDATA 350 HUDSON ST 9TH FLOOR NEW YORK NY 10014 DATA SERVICES 441610 BERRY CONSULTANTS LLC 3345 BEE CAVES RD STE 201 AUSTIN TX 78746 STATISTICAL CONSULTATION 275720 MEDQIA 1171 S ROBERTSON BLVD PMB 414 LOS ANGELES CA 90035 DATA SERVICES 189335 WILSON SONSINI GOODRICH & ROSATI 650 PAGE MILL ROAD PALO ALTO CA 94304 LEGAL SERVICES 123349 5 1028577 1028577 TRIAL REVENUE 541700 29534891 29534891 29534891 1880695 1880695 32444163 29534891 0 1880695 X 18708 18708 962 962 3841620 2898502 943118 2990460 2290842 699618 127181 95958 31223 433083 326761 106322 449592 339217 110375 109138 109138 68188 68188 78406 78406 21390718 21390718 8884 8884 47830 9196 38634 165702 9101 156601 13642 13642 284109 47983 236126 88398 1596 86802 133690 11666 122024 DOUBTFUL ACCOUNTS 2357498 2357498 32607809 29907846 2699963 0 874264 1752751 3948737 6292172 702464 510058 4705822 2512011 3555673 4406550 37399235 43639539 12416075 19036694 63602270 78149775 5722820 10164536 18132292 23506032 500000 250000 24355112 33920568 X 39247158 44229207 39247158 44229207 63602270 78149775 -163646 5145695 0 X 0 1 X 1 0 X 504130 543271 3081228 1668304 1028577 6825510 504130 543271 3081228 1668304 1028577 6825510 4492369 2333141 5504 483944 1733052 1854131 1880695 5957326 12782836 150224112 0.18250 0.25770 X GLOBAL COALITION FOR ADAPTIVE RESEARCH, INC. ("GCAR") ACKNOWLEDGES ITS PERCENTAGE OF PUBLIC SUPPORT FOR THE LATEST COMPUTATION PERIOD FALLS BELOW THE ONE-THIRD THRESHOLD AND RESPECTFULLY SUBMITS THAT IT QUALIFIES AS A PUBLICLY SUPPORTED GCAR UNDER THE FACTS AND CIRCUMSTANCES TEST BASED ON THE FOLLOWING FACTORS.1. PUBLIC SUPPORT PERCENTAGE: FOR THE RELEVANT COMPUTATION PERIOD, GCAR'S PUBLIC SUPPORT CONSTITUTES APPROXIMATELY 18.25 % OF TOTAL SUPPORT, WHICH MEETS THE 10% MINIMUM THRESHOLD REQUIRED UNDER THE FACTS AND CIRCUMSTANCES TEST. TRADITIONALLY, GCAR PUBLIC SUPPORT HAS BEEN RECEIVED FROM LIKE- MINDED CHARITABLE ORGANIZATIONS AND PATIENT ADVOCACY GROUPS, REFLECTING ONGOING EXTERNAL VALIDATION OF GCAR'S RESEARCH MISSION BY INDEPENDENT INSTITUTIONS WITH THEIR OWN CHARITABLE PURPOSES AND GOVERNANCE AND HAS REMAINED STEADY IN THE PRIOR FIVE YEARS . THE DECLINE IN THE RATIO IS ATTRIBUTABLE PRIMARILY TO GROWTH IN INVESTMENT INCOME (FROM $5.5K IN 2021 TO $1.88 MILLION IN 2025) DERIVED FROM THE DISCIPLINED STEWARDSHIP OF RESEARCH SURPLUSES, NOT TO ANY REDUCTION IN THE ABSOLUTE LEVEL OF PUBLIC CONTRIBUTIONS RECEIVED.2. NATURE OF GCAR'S SUPPORT; ATTRACTION OF PUBLIC SUPPORT: GCAR'S PUBLIC SUPPORT HAS BEEN TRADITIONALLY DERIVED FROM GRANTS FROM LIKE-MINDED CHARITABLE ORGANIZATIONS BASED ON THEIR INDEPENDENT ASSESSMENT OF THE SCIENTIFIC MERIT AND PUBLIC HEALTH VALUE OF GCAR'S MISSION . THEIR SUPPORT REFLECTS AN ARM'S-LENGTH DETERMINATION BY SOPHISTICATED INSTITUTIONAL FUNDERS AND EVIDENCES GENUINE PUBLIC ENDORSEMENT OF GCAR'S MISSION. IN ADDITION, GCAR ALSO MAINTAINS PARTNERSHIPS WITH FOR-PROFIT COMPANIES, WHICH ARE STRUCTURED AS SPONSORED RESEARCH AGREEMENTS IN WHICH FOR-PROFIT ENTITIES FUND GCAR'S CHARITABLE RESEARCH ACTIVITIES AND WHICH GENERATE SUBSTANTIAL PROGRAM FEES. THESE ARRANGEMENTS ARE PROGRAM-RELATED IN NATURE AND REFLECT EXTERNAL VALIDATION OF GCAR'S SCIENTIFIC CAPABILITIES AND THE PUBLIC VALUE OF ITS RESEARCH.HOWEVER, GCAR UNDERSTANDS THE IMPORTANCE OF MAINTAINING A BROAD AND PUBLICLY FUNDED BASE OF SUPPORT AND HAS TAKEN AND CONTINUES TO TAKE AFFIRMATIVE STEPS TO ATTRACT SUPPORT FROM GOVERNMENTAL UNITS, PUBLIC CHARITIES, AND THE PUBLIC: - GCAR HAS SOLICITED AND ENGAGED WITH OUTSIDE FUNDRAISERS TO EXPLORE PLANS TO DEVELOP AND/OR BROADEN GCAR'S PUBLIC FUNDRAISING STRATEGY AND SUPPORT BASE.- GCAR MAINTAINS ACTIVE RELATIONSHIPS AND COLLABORATIONS WITH DONATIVE PUBLIC CHARITIES, INCLUDING THE SOLICITATION OF FUNDS, (E.G., THE NATIONAL BRAIN TUMOR SOCIETY, PANCREATIC CANCER ACTION NETWORK, THE CHOLANGIOCARCINOMA FOUNDATION, THE CHILDREN'S TUMOR FOUNDATION).- GCAR INTENDS TO IMPLEMENT COLLABORATIVE AND MISSION-SPECIFIC FUNDRAISING WITH CERTAIN PUBLIC CHARITIES IN THE NEAR FUTURE, INCLUDING BUT NOT LIMITED TO MAJOR FUNDERS IN RESEARCH IN BRAIN CANCER, PANCREATIC CANCER, GASTROINTESTINAL CANCER, OVARIAN CANCER AND NEUROFIBROMATOSIS. GCAR IS IN ACTIVE DISCUSSION WITH THESE LIKE-MINDED PUBLIC CHARITIES, AND, UPON FINALIZATION, THESE INITIATIVES ARE EXPECTED TO INCREASE PUBLIC CONTRIBUTIONS TO GCAR MEANINGFULLY IN FUTURE COMPUTATION PERIODS.- GCAR HAS TAKEN OTHER STEPS (E.G., INCREASED SOCIAL MEDIA PRESENCE, PUBLICATION OF MASTER PROTOCOL WHITE PAPERS, SPONSORSHIP OF CHARITABLE EVENTS, SOLICITATION OF GIFTS THROUGH ITS WEBSITE) TO EXPAND ITS PUBLIC PROFILE AND DRIVE PHILANTHROPIC INTEREST IN ITS ORGANIZATION.3. PUBLIC BENEFIT: PROGRAM ACTIVITIES AND RESEARCH OUTPUT: GCAR'S MISSION IS THE PIONEERING OF COLLABORATIVE, INNOVATIVE CLINICAL TRIALS TO SPEED THE DISCOVERY AND DEVELOPMENT OF CURES. GCAR HAS ACCOMPLISHED THIS THROUGH ITS SPONSORSHIP OF INNOVATIVE CLINICAL TRIALS, INCLUDING REMAP-COVID (EVALUATING COVID-19 TREATMENTS), M-PACT (PARTNERING WITH THE US GOVERNMENT TO EVALUATE PTSD TREATMENTS FOR US SOLDIERS) AND MOST PRIMARILY ITS GBM AGILE MASTER PROTOCOL, WHICH AIMS TO FIND A CURE FOR THE MOST COMMON AND AGGRESSIVE FORM OF BRAIN CANCER: GLIOBLASTOMA. GLIOBLASTOMA HAS NO KNOWN CURE AND THE PROGNOSIS FOR DIAGNOSED PATIENTS IS BLEAK : MEDIAN OVERALL SURVIVAL IS <18 MONTHS, AND ONLY APPROX. 12 MONTHS IN CERTAIN INDICATIONS. IN ADDITION, RESEARCH INTO THIS DISEASE HAD STALLED PRIOR TO GBM AGILE: NO NEW TREATMENTS HAVE BEEN APPROVED FOR ANY FORM OF GLIOBLASTOMA IN THE PAST TEN YEARS AND THE CURRENT STANDARD OF CARE FOR NEWLY-DIAGNOSED GLIOBLASTOMA WAS APPROVED TWENTY YEARS AGO. THIS REALITY UNDERSCORES THE URGENT NEED FOR THE TYPE OF INNOVATIVE THERAPEUTIC APPROACHES TO BENEFIT PATIENTS THAT GCAR PROVIDES. AS OF THE PRESENT DAY, GBM AGILE IS OPEN IN SIXTY INSTITUTIONAL SITES/HOSPITALS ACROSS THE COUNTRY AND HAS EVALUATED/OR IS IN THE PROCESS OF EVALUATING 8 SEPARATE INVESTIGATIONAL TREATMENTS IN THIS DISEASE SPACE; AS OF JULY 2025, GBM AGILE HAD SCREENED MORE THAN 2300 PATIENTS, AND ESTIMATES ITS CURRENT ACTIVE ENROLLMENT ACCOUNTS FOR APPX. 10% OF ALL GLIOBLASTOMA CLINICAL RESEARCH SUBJECTS. NOT ONLY DO THESE METRICS REPRESENT THE GENERATION OF USEFUL DATA THAT WILL BE USED TO DRIVE RESEARCH INTO THIS DISEASE, BUT THE PROVISION OF CONCRETE HOPE AND OPPORTUNITY TO AN UNDERSERVED PATIENT POPULATION.IN ADDITION TO THIS PATIENT IMPACT, GCAR HAS BEGUN MAKING ITS RESEARCH DATA AND FINDINGS PUBLICLY AVAILABLE THROUGH ITS COLLABORATION WITH RESEARCH INSTITUTIONS AND INVESTIGATORS PARTICIPATING IN GCAR TRIALS, SCIENTIFIC PUBLICATIONS , AND CONFERENCE PRESENTATIONS . THIS PUBLIC DISSEMINATION OF RESEARCH OUTPUT REFLECTS GCAR'S COMMITMENT TOWARD PUBLIC BENEFIT, ENSURING THE BENEFITS OF GCAR'S WORK ARE ACCESSIBLE TO THE SCIENTIFIC COMMUNITY AND TO PATIENTS, AND ARE NOT RESTRICTED TO ITS COMMERCIAL RESEARCH PARTNERS.IN ADDITION TO THE ABOVE, GCAR IS COMMITTED TO MAXIMIZING THE IMPACT OF ITS CHARITABLE ASSETS AND TO ITS PUBLIC TRANSPARENCY. GCAR HAS TRADITIONALLY DEVOTED APPROX. 90% OF ITS EXPENSES TO THE ADVANCEMENT OF ITS CHARITABLE PROGRAMS AND CURRENTLY MAINTAINS PLATINUM TRANSPARENCY STATUS ON THE GUIDESTAR/CANDID CHARITABLE WATCHDOG DATABASE. 4. COMPOSITION AND INDEPENDENCE OF THE GOVERNING BODY: AS OF 2025, GCAR'S BOARD OF DIRECTORS IS COMPOSED OF 8 MEMBERS WHO SERVE IN A WHOLLY VOLUNTARY CAPACITY AND DO NOT RECEIVE COMPENSATION FOR THEIR SERVICES AS BOARD MEMBERS. THE BOARD IS MADE UP OF A DIVERSE GROUP OF INDIVIDUALS INCLUDING RECOGNIZED SCIENTIFIC THOUGHT LEADERS HOLDING ACADEMIC APPOINTMENTS AT INDEPENDENT RESEARCH UNIVERSITIES (E.G., UCLA AND MD ANDERSON), AS WELL AS BUSINESS LEADERS AND ONCOLOGICAL AND CLINICALLY FOCUSED EXECUTIVES. NO SINGLE COMMERCIAL INTEREST, FOR-PROFIT PARTNER, OR PRIVATE PARTY CONTROLS OR HOLDS DISPROPORTIONATE INFLUENCE OVER THE BOARD. THE BOARD'S COMPOSITION REFLECTS THE IMPORTANCE OF THE SCIENTIFIC AND PATIENT COMMUNITIES TO GCAR'S MISSION AND PROVIDES AN INDEPENDENT CHECK ON GCAR'S OPERATIONS THAT IS CHARACTERISTIC OF PUBLICLY ORIENTED CHARITABLE ORGANIZATIONS.5. NATURE OF RESEARCH ACTIVITIES AND FOR-PROFIT PARTNERSHIPS: GCAR'S SPONSORED RESEARCH AGREEMENTS WITH FOR-PROFIT COMPANIES ARE CONSISTENT WITH ITS PUBLIC CHARITY MISSION. UNDER THESE AGREEMENTS, FOR-PROFIT PARTNERS FUND GCAR TO CONDUCT INDEPENDENT RESEARCH IN HIGH-NEED PATIENT POPULATIONS. GCAR RETAINS OVERALL RESPONSIBILITY FOR ITS STUDY DESIGN AND ENDPOINTS AS WELL AS DECISION-MAKING AND LEADERSHIP OF ITS TRIALS, CONSISTENT WITH SPONSORSHIP. GCAR ALSO RETAINS OWNERSHIP OF ALL DATA GENERATED ON ITS TRIALS AS WELL AS RELATED PUBLICATION RIGHTS CONSISTENT WITH ITS COMMITMENT TO THE PUBLIC'S BENEFIT FROM ITS FINDINGS. GCAR DOES NOT PERMIT THE RESULTS OF ITS TRIALS TO BE SHELVED OR OTHERWISE REMOVED FROM THE PUBLIC AND IS COMMITTED TO THE TIMELY PUBLICATION OF ALL RESULTS OF ITS STUDIES. GCAR IS ALSO ACTIVELY ENGAGED IN EVALUATING WAYS TO REDEPLOY THIS DATA TO BETTER THE PATIENT COMMUNITY (E.G., CREATION OF A LEARNING ENVIRONMENT USING GENERATED DATA, CONTRIBUTION TO PATIENT DATABASES, AND/OR FOSTERING NEW TRIALS IN NEW DISEASE SPACES).FINALLY, THE SURPLUSES GENERATED FROM THESE ARRANGEMENTS ARE MAINTAINED AND DEDICATED TO GCAR'S CHARITABLE MISSION AND DO NOT INURE TO ANY PRIVATE INTEREST. GCAR HAS TRADITIONALLY, CONSERVATIVELY INVESTED ANY SURPLUSES GENERATED TO PRESERVE ITS FINANCIAL STABILITY AND ENSURE ITS LONG-TERM CAPACITY TO PURSUE ITS MISSION. GCAR DOES NOT VIEW THESE INVESTMENT RETURNS AS A PERMANENT FEATURE OF ITS SUPPORT PROFILE AND ANTICIPATES REDEPLOYING THESE ASSETS TO STRATEGICALLY ADVANCE ITS CHARITABLE OBJECTIVES. PART II, SECTION C, LINE 17A, FACTS AND CIRCUMSTANCES TEST: 6. FORWARD-LOOKING STATEMENT: GCAR IS ACTIVELY WORKING TO RESTORE ITS PUBLIC SUPPORT RATIO TOWARD THE ONE-THIRD THRESHOLD. AS NOTED ABOVE, AS GCAR'S INVESTMENT POOL IS REALLOCATED, THE RELATIVE WEIGHT OF INVESTMENT INCOME IN THE SUPPORT CALCULATION IS EXPECTED TO DECREASE. IN ADDITION, TO DRIVE PUBLIC SUPPORT, GCAR WILL CONTINUE TO EXPLORE PLANS TO EXPAND ITS BASE OF SUPPORT, POTENTIALLY THROUGH OUTSIDE FUNDRAISING AND/OR IN COLLABORATION WITH CHARITABLE PARTNERS. CURRENTLY GCAR ANTICIPATES BEING ABLE TO GENERATE INCREASED PUBLIC CONTRIBUTIONS, POTENTIALLY BEGINNING AS SOON AS 2026, THROUGH DYNAMIC, COLLABORATIVE AND MISSION-CENTRIC FUNDRAISING ENGAGEMENTS WITH IDENTIFIED LIKE-MINDED PUBLIC CHARITIES. FINALLY, GCAR WILL CONTINUE TO MAKE ITS DATA AND RESEARCH FINDINGS PUBLICLY AVAILABLE, WHICH IT EXPECTS WILL INCREASE PUBLIC AWARENESS OF ITS MISSION AND DRIVE OVERALL PHILANTHROPIC INTEREST OVER TIME. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 MONEY MARKET FUNDS 19036694 F 19036694 REFUNDABLE ADVANCE 250000 250000 37556349 5145695 44897 -78406 5112186 32444163 0 32444163 32574300 44897 44897 32529403 78406 78406 32607809 PART XI, LINE 2D - OTHER ADJUSTMENTS: INVESTMENT FEES -78,406. 1 NATIONAL BRAIN TUMOR SOCIETY 55 CHAPEL STREET SUITE 006 NEWTON MA 02458 043068130 501(C)(3) 10000 0 GBM AWARENESS DAY AND WALK SPONSORSHIP 1 0 PART I, LINE 2: THE GRANTS WE ISSUED WERE UNRESTRICTED AND ARE INTENDED TO HELP SUPPORT THE RESPECTIVE ORGANIZATION'S MISSION. WE HAVE ASKED EACH ORGANIZATION TO KEEP ALL RECORDS OF THE USE OF THE GIFT IN THE NORMAL COURSE OF BUSINESS AND PROVIDE COPIES UPON REQUEST. X X X 0 0 0 0 0 0 0 0 0 MEREDITH BUXTON CHIEF EXECUTIVE OFFICER/PRESIDENT 669450 0 600000 0 0 0 14000 0 38165 0 1321615 0 0 0 ROBERT MURRAY CHIEF BUSINESS AND STRATEGY OFFICER 392076 0 420385 0 0 0 14000 0 1200 0 827661 0 0 0 RACHAEL COLEMAN CFO/COO/TREASURER 391250 0 150000 0 0 0 14000 0 17098 0 572348 0 0 0 ASHLEY POWELL VICE PRESIDENT, TRIAL OPERATIONS 320625 0 200000 0 0 0 12825 0 1057 0 534507 0 0 0 RACHEL ROSENSTEIN SISSON COMMUNITY ENGAGEMENT/TRAINING LEAD 166440 0 100000 0 0 0 6656 0 12902 0 285998 0 0 0 TRACEY ROBERTS DIRECTOR, QUALITY AND NEW INITIATIVE 218400 0 36750 0 0 0 8736 0 21339 0 285225 0 0 0 MATTHEW VIVA DIRECTOR, LEGAL/SECRETARY 207900 0 37450 0 0 0 9018 0 22226 0 276594 0 0 0 SARAH UNTCH DIRECTOR, TRIAL OPERATIONS 209459 0 37450 0 0 0 8902 0 20217 0 276028 0 0 0 HEATHER KLING DIRECTOR, CLINICAL SCIENCE 186554 0 29750 0 0 0 7602 0 12411 0 236317 0 0 0 TIMOTHY CLOUGHESY MD CHIEF MEDICAL OFFICER AND DIRECTOR 215625 0 0 0 0 0 0 0 0 0 215625 0 0 0 NAWEEN TAMJIDI SR. MGR,TRIAL OPERATIONS 169003 0 28880 0 0 0 6864 0 9531 0 214278 0 0 0 FORM 990, PART VI, SECTION A, LINE 4 THE MISSION OF THE ORGANIZATION WAS MODIFIED FROM TO LEAD THE DEVELOPMENT AND ONGOING MANAGEMENT OF CLINICAL TRIAL PLATFORMS TO ACCELERATE THE DISCOVERY AND DEVELOPMENT OF TREATMENTS FOR PATIENTS WITH RARE AND DEADLY DISEASES TO PIONEERING COLLABORATIVE, INNOVATIVE CLINICAL TRIALS TO SPEED THE DISCOVERY AND DEVELOPMENT OF CURES. FORM 990, PART VI, SECTION B, LINE 11B THE CFO/COO/TREASURER WILL REVIEW WITH ACCOUNTING FIRM. ONCE NEAR FINAL WILL REVIEW WITH CEO/PRESIDENT. WHEN FORM IS FINAL, FORM IS REVIEWED WITH THE ENTIRE BOARD. FORM 990, PART VI, SECTION B, LINE 12C EACH DIRECTOR AND OFFICER IS REQUIRED TO SUBMIT AN UPDATED CONFLICT OF INTEREST STATEMENT ON AN ANNUAL BASIS. TO THE EXTENT THAT RELATIONSHIPS ARE IDENTIFIED VIA THESE STATEMENTS AND OTHER INFORMATION, THE INDIVIDUAL'S CONSTITUENT RECORD IN THE COMPANY DATABASE IS UPDATED TO INCLUDE THIS INFORMATION, FACILITATING PERIODIC QUERIES, AS NECESSARY. ANY BOARD MEMBER WITH A CONFLICT MUST IDENTIFY THE CONFLICT AT ANY BOARD MEETING WHERE THE CONFLICT IS RELEVANT. THE MEMBER CANNOT BE PRESENT AT ANY PART OF THE MEETING WHERE THE RELEVANT TOPIC IS DISCUSSED OR VOTED ON. THE MEMBER CANNOT BE COUNTED FOR A QUORUM. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION COMMITTEE AND BOARD OF DIRECTORS ARE RESPONSIBLE FOR THE REVIEW AND APPROVAL OF TOP LEVEL EXECUTIVE MANAGEMENT COMPENSATION ANNUALLY. INDEPENDENT PROFESSIONAL EXPERTS ARE CALLED UPON FOR HIGHER LEVEL POSITIONS AND ASSIST IN ESTABLISHING EXECUTIVE SALARIES IN THE COMPETITIVE MARKETPLACE. SALARIES IN BOTH FOR PROFIT AND NOT FOR PROFIT ORGANIZATIONS ARE EVALUATED WITH THE INTENT ON ENSURING THAT THE EXECUTIVE COMPENSATION PROGRAM FALLS WITHIN A REASONABLE RANGE OF COMPETITIVE PRACTICES FOR COMPARABLE POSITIONS AMONG SIMILARLY SITUATED ORGANIZATIONS. THE REVIEW INCLUDES INCENTIVE PLANS AND ALL FRINGE BENEFITS AS WELL AS BASE SALARY ARRANGEMENTS. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART IX, LINE 11G TRIAL EXPENSES: PROGRAM SERVICE EXPENSES 21,390,718. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 21,390,718. SPARK COALITION INC 700 LARKSPUR LANDING CIR STE 199 LARKSPUR CA 94939 394576893 SUPPORT GLOBAL COALITION FOR ADAPTIVE RESEARCH, INC. DE 501(C)(3) LINE 12A, I GLOBAL COALITION FOR ADAPTIVE RESEARCH INC 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0